HistoryPedia - Внесок користувача [uk]

SMolecular Cancer BiologyFigure 1. Intraindividual heterogeneity between liver metastases as determined by

2017-12-11T15:27:32Z

Dogperiod37:

Intraindividual heterogeneity between liver metastases as determined by [https://www.medchemexpress.com/GDC-0084.html GDC-0084] different [https://www.medchemexpress.com/Fruquintinib.html MedChemExpress HMPL-013] mutation status for one or more of the genes TP53, KRAS, BRAF and PIK3CA. Notably, in five patients, KRAS or TP53 mutations seemed to evolve over time either between the primary and the metastases or between the first and second liver resection (see details in Supporting Information Table S2). Cancer: 139, 647?56 (2016) V 2016 The Authors International Journal of Cancer published by John Wiley Sons Ltd on behalf of Union for International Cancer ControlL s et al.Influence of chemotherapy exposureFigure 2. Kaplan eier survival curves illustrating time to relapse (left panels) and disease-specific survival (right panels) after liver surgery for metastatic colorectal cancer with respect to mutation status for KRAS, BRAF, KRAS [https://dx.doi.org/10.1080/02699931.2015.1049516 title= 02699931.2015.1049516] and BRAF combined, PIK3CA and TP53 (n 5 151 in each panel). A patient was classified as harboring a gene mutation as long as it was present in at least one lesion. pvalues are from log-rank tests.Mutation status and prognosis after liver resectionTo evaluate the prognostic impact of the mutations described above in patients treated with liver resections, we excluded patients who had undergone a previous liver resection (n 5 13) before inclusion in the present study, leaving a total of 151 patients. In univariate analyses (Fig. 2), we found KRAS and BRAF mutations both to be associated with reduced median TTR (7 vs. 22 and 3 vs. 16 months; p [https://dx.doi.org/10.1038/srep43317 title= srep43317] Comparing all the four treatment groups together, a significant effect on TRR (p

SMolecular Cancer BiologyFigure 1. Intraindividual heterogeneity between liver metastases as determined by

2017-12-07T11:21:41Z

Dogperiod37:

Notably, in five patients, KRAS or TP53 mutations seemed to evolve over time either between the primary and the metastases or between the first and second liver resection (see details in [http://brantzegfamily.com/members/liquid68diving/activity/167901/ Tions at opposite locations (red) and within-object locations (blue) plotted against] Supporting Information Table S2). Mutation frequencies in subgroups of patients with different chemotherapy exposure are listed in Supporting Information Table S3.C Int. J. Cancer: 139, 647?56 (2016) V 2016 The Authors International Journal of Cancer published by John Wiley Sons Ltd on behalf of Union for International Cancer ControlL s et al.Influence of chemotherapy exposureFigure 2. Kaplan eier survival curves illustrating time to relapse (left panels) and disease-specific survival (right panels) after liver surgery for metastatic colorectal cancer with respect to mutation status for KRAS, BRAF, KRAS [https://dx.doi.org/10.1080/02699931.2015.1049516 title= 02699931.2015.1049516] and BRAF combined, PIK3CA and TP53 (n 5 151 in each panel). A patient was classified as harboring a gene mutation as long as it was present in at least one lesion. pvalues are from log-rank tests.Mutation status and prognosis after liver resectionTo evaluate the prognostic impact of the mutations described above in patients treated with liver resections, we excluded patients who had undergone a previous liver resection (n 5 13) before inclusion in the present study, leaving a total of 151 patients. In univariate analyses (Fig. 2), we found KRAS and BRAF mutations both to be associated with reduced median TTR (7 vs. 22 and 3 vs. 16 months; p [https://dx.doi.org/10.1038/srep43317 title= srep43317] Comparing all the four treatment groups together, a significant effect on TRR (p

Of Cancer published by John Wiley Sons Ltd on behalf of

2017-12-07T09:44:44Z

Dogperiod37:

Kaplan eier survival curves illustrating differences in time to relapse (left panels) and disease-specific survival (right panels) after liver surgery for metastatic colorectal cancer [https://www.medchemexpress.com/fosamprenavir-calcium-salt.html GW433908G web] Comparing patients harboring no mutations to patients harboring intraindividual mutation heterogeneity across either KRAS, BRAF, TP53 or PI3K and patients revealing at least one homogenous but no heterogeneous mutation in either gene (a). double wt) [https://www.medchemexpress.com/Ganetespib.html STA-9090 manufacturer] Chemotherapy1 1.08 0.93 1.55 2.00 1.73 0.92 1.12 2.34 0.39 95 CI (0.71, 1.65) (0.62, 1.40) (0.97, 2.48) (1.21, 3.29) (1.11, 2.68) (0.61,1.42) (0.63, 1.97) (1.50, 3.66) (0.23, 0.64) p values 0.720 0.726 0.064 0.007 0.015 0.720 0.700 [https://dx.doi.org/10.1186/1479-5868-9-35 title= 1479-5868-9-35] patients harboring a homogeneous mutation in at least one gene across all metastatic deposits and with no heterogeneous mutation and (iii) patients with no mutations across either gene. Comparing all three groups, univariate analysis revealed asignificant different TTR (median of 4 vs. 5 vs. 15 months, p [https://dx.doi.org/10.1002/ejsp.2064 title= ejsp.2064] 58 months, p 65 years) Sex (male vs. female) Nodal status of primary (N1 vs. N0) Synchronous vs. metachronous mets.

Of Cancer published by John Wiley Sons Ltd on behalf of

2017-12-04T19:24:46Z

Dogperiod37: Створена сторінка: Kaplan eier survival curves illustrating differences in time to relapse (left [https://www.medchemexpress.com/fosamprenavir-calcium-salt.html GW433908G web] pan...

Kaplan eier survival curves illustrating differences in time to relapse (left [https://www.medchemexpress.com/fosamprenavir-calcium-salt.html GW433908G web] panels) and disease-specific survival (right panels) after liver surgery for metastatic colorectal cancer comparing patients [https://www.medchemexpress.com/Ganetespib.html STA-9090] harboring no mutations to patients harboring intraindividual mutation heterogeneity across either KRAS, BRAF, TP53 or PI3K and patients revealing at least one homogenous but no heterogeneous mutation in either gene (a). double wt) Chemotherapy1 1.08 0.93 1.55 2.00 1.73 0.92 1.12 2.34 0.39 95 CI (0.71, 1.65) (0.62, 1.40) (0.97, 2.48) (1.21, 3.29) (1.11, 2.68) (0.61,1.42) (0.63, 1.97) (1.50, 3.66) (0.23, 0.64) p values 0.720 0.726 0.064 0.007 0.015 0.720 0.700 [https://dx.doi.org/10.1186/1479-5868-9-35 title= 1479-5868-9-35] patients harboring a homogeneous mutation in at least one gene across all metastatic deposits and with no heterogeneous mutation and (iii) patients with no mutations across either gene. Comparing all three groups, univariate analysis revealed asignificant different TTR (median of 4 vs. 5 vs. 15 months, p [https://dx.doi.org/10.1002/ejsp.2064 title= ejsp.2064] 58 months, p

Ed in the trials. In animal models, 1 kavalactone, kavain, appeared

2017-11-25T11:43:12Z

Dogperiod37: Створена сторінка: Moreover, a number of the gains had been maintained at one-week follow-up. At this time point, placebo was linked using a additional improve of extra 24 minutes...

Moreover, a number of the gains had been maintained at one-week follow-up. At this time point, placebo was linked using a additional improve of extra 24 minutes of total sleep time. Taken collectively, these trials usually do not deliver convincing support for the efficacy of L-tryptophan for insomnia. With respect to security, the sale of tryptophan was banned within the USA from 1991 to 2001 following a big tryptophanrelated outbreak of eosinophilia-myalgia syndrome (EMS) top to 37 deaths. Sales resumed in 2001, but cautions associated to worsening of liver and kidney illness remain as a result of hyperlink to EMS [54, 55]. It really is also listed as "likely unsafe" for pregnant or breastfeeding ladies. On its own, tryptophan is typically safe with mild side effects that consist of gastrointestinal [https://dx.doi.org/10.3758/s13415-015-0346-7 title= s13415-015-0346-7] unwanted effects also as headac.Ed in the trials. In animal models, one kavalactone, kavain, appeared to change sleep micro- and macroarchitecture in comparison with other sedatives [42]. An analogous trial has not been conducted in humans. In truth, virtually no randomized, controlled trials have explored the efficacy of kava kava in treatment for insomnia and the couple of published trials have usually included sleep metrics as a secondary outcome measure. A poorly performed trial published in 2004 examined the influence of a kava extract on sleep scores on a validated sleep questionnaire in subjects with baseline anxiety [43]. Following excluding many prospective subjects, the authors compared 34 subjects taking kava extract to 27 subjects taking placebo. They saw a statistically substantial advantage to kava when compared with baseline in their predetermined metrics, but both groups saw important improvements. In the absence of higher [http://campuscrimes.tv/members/driverleek0/activity/566133/ Communities: a participatory analysis study. Sex Transm Infect 2002;78:241-5.Well being requires] high-quality,4 randomized controlled trials, there is clear opportunity to explore the efficacy of kava in major insomnia. Kava has been subject to a variety of safety issues, and this itself is often a matter of controversy [44]. The principal one particular amongst these is the possibility of hepatotoxicity. Because of issues about this distinct side impact as well as other regulatory matters, kava has been highly restricted, especially inside the European Union where it had been banned from import to get a number of years. Quite a few authors have recommended that the mode of preparation from the kava extract, such as what portion on the plant is employed, can play [https://dx.doi.org/10.1163/1568539X-00003152 title= 1568539X-00003152] a function in this toxicity. There is suggestion that preparations made in the root of the plant are generally secure, whereas other portions in the plant, for example the stems or leaves, may be extra toxic [45]. Likewise, there is some speculation that the method of extraction, especially the solvents employed within the approach instead of the plant-based compounds themselves, may be the correct offending concern [46].Evidence-Based Complementary and Option Medicine three-arm RCT ( = 49) compared one-week administration of a food sourced tryptophan (butternut squash seed) to pharmaceutical grade tryptophan plus a carbohydrate alone (placebo), all prepared in food bars. Within this study, both types of L-tryptophan resulted in considerable improvement on sleep diary measures of insomnia, but similar improvements had been noted in the placebo condition such that no important group ?time interactions were observed [53]. The biggest improvement was in total sleep time having a 19- minute enhance inside the squash seed condition plus a 42-minute increase inside the tryptophan supplement situation, although there was also a 17-minute improve within the placebo condition.

317. 16. Waterfield J. Is pharmacy a knowledge-based profession? Am J Pharm Educ.

2017-11-24T17:27:16Z

Dogperiod37:

[https://www.medchemexpress.com/GDC-0068.html GDC-0068 biological activity] Perspect Biol Med. J Overall health Care Law Policy. 2007;10(1):61--88. 14.317. 16. Waterfield J. Is pharmacy a knowledge-based profession? Am J Pharm Educ. 2010;74(three):Write-up 50. 17. Queensland Government. Well being Practitioner Regulation National Law (Queensland). 2014. https://www.legislation.qld.gov. au/LEGISLTN/CURRENT/H/HealthPracRNatLaw.pdf. Accessed December 29 2014. 18. Hafferty FW, Levinson D. Moving beyond nostalgia and motives: towards a complexity science view of health-related professionalism. Perspect Biol Med. 2008;51(four):599-615. 19. Van de Camp K, Vernooij-Dassen MJ, Grol RP, Bottema BJ. How you can conceptualise professionalism: a qualitative study. Med Teach. 2004;26(eight):696-702. 20. van Mook WN, van Luijk SJ, O'Sullivan H, et al. The concepts of professionalism and specialist behaviour: conflicts in both definition and mastering outcomes. Eur J Intern Med. 2009;20(four): e85-89. 21. Wilson S, Tordoff, A., Beckett, G. Pharmacy professionalism: a systematic evaluation of contemporary literature (1998-2009). Pharm Educ. 2010;ten(1):27-32. 22. Riley S, Kumar N. Teaching health-related professionalism. Clin Med. 2012;12(1):9-11. 23. Monrouxe LV, Rees CE, Hu W. Variations in healthcare students' explicit discourses of professionalism: acting, representing, becoming. Med Educ. 2011;45(6):585-602. 24. Hafferty FW. Definitions of professionalism: a search for [https://dx.doi.org/10.1186/s12889-015-2195-2 title= s12889-015-2195-2] meaning and identity. Clin Orthop Relat Res. 2006;449:193-204. 25. American Board of Internal medicine. Project Professionalism. Philadelphia PA; 1995. 26. ABIM Foundation. American Board of Internal Medicine. [https://dx.doi.org/10.1037/a0022827 title= a0022827] Healthcare professionalism within the new millennium: a doctor charter. Ann Intern Med. 2002;136(3):243?46. 27. Traulsen JM, Bissel P. Theories of professions and also the pharmacist. Int J Pharm Pract. 2004;12(two):107-114. 28. Zijlstra-Shaw S, Robinson PG, Roberts T. Assessing professionalism within dental education; the need to get a definition. Eur J Dent Educ. 2012;16(1):e128-136. 29. Mossop LH. Is it time to define veterinary professionalism? J Vet Med Educ. 2012;39(1):93-100. 30. Schafheutle EI, Hassell K, Ashcroft DM, Hall J, Harrison S. How do pharmacy students find out professionalism? Int J Pharm Pract. 2012;20(2):118-128. 31. Brown D, Ferrill MJ. The taxonomy of professionalism: reframing the academic pursuit of qualified development. Am J Pharm Educ. 2009;73(four):68. 32. Noble C, O'Brien M, Coombes I, Shaw PN, Nissen L, Clavarino A. Becoming a pharmacist: Students' perceptions of their curricular knowledge and expert identity formation. Curr Pharm Teach Discover. 2014;six(3):327-339. 33. Evetts J. Professionalism: Value and ideology. Present Sociology. September 1, 2013 2013;61(5-6):778?96. 34. APhA-ASP/AACP-COD Activity Force on Professionalism. White paper on pharmacy student professionalism. J Am Pharm Assoc. 2000;40:96-102. 35. AACP Job Force on Professionalism. Report on the AACP Professionalism Process Force. Am J Pharm Educ. 2011;10. Science, politics, and values: the politicization of experienced practice recommendations. JAMA. 2009;301(six):665---667. 12. Kinney E. Administrative law and also the public's overall health. J Law Med Ethics. 2002;30(2):212---223. 13. Richards EP. Public well being law as administrative law: example lessons. J Wellness Care Law Policy. 2007;10(1):61--88.

317. 16. Waterfield J. Is pharmacy a knowledge-based profession? Am J Pharm Educ.

2017-11-22T23:44:21Z

Dogperiod37:

Pharmacy professionalism: a systematic analysis of [http://anomalysa.co.za/members/drawer02cocoa/activity/149106/ Ol of Medicine, London SE11 6SP roger.jones@kcl.ac.ukCompeting] contemporary literature (1998-2009). The taxonomy of professionalism: reframing the academic pursuit of experienced improvement. Am J Pharm Educ. 2009;73(four):68. 32. Noble C, O'Brien M, Coombes I, Shaw PN, Nissen L, Clavarino A. Becoming a pharmacist: Students' perceptions of their curricular experience and expert identity formation. Curr Pharm Teach Understand. 2014;6(3):327-339. 33. Evetts J. Professionalism: Worth and ideology. Present Sociology. September 1, 2013 2013;61(5-6):778?96. 34. APhA-ASP/AACP-COD Task Force on Professionalism. White paper on pharmacy student professionalism. J Am Pharm Assoc. 2000;40:96-102. 35. AACP Job Force on Professionalism. Report of your AACP Professionalism Process Force. Am J Pharm Educ. 2011;10. 36. Roth MT, Zlatic TD. Improvement of student professionalism. Pharmacotherapy. 2009;29(six):749-756.Well being POLICY AND ETHICS10. Bennett JT, DiLorenzo TJ. From Pathology to Politics: Public Wellness in America. New Brunswick, NJ: Transaction Publishers; 2000. 11. Kraemer JD, Gostin LO. Science, politics, and values: the politicization of expert practice suggestions. JAMA. 2009;301(6):665---667. 12. Kinney E. Administrative law along with the public's health.317. 16. Waterfield J. Is pharmacy a knowledge-based profession? Am J Pharm Educ. 2010;74(3):Post 50. 17. Queensland Government. Well being Practitioner Regulation National Law (Queensland). 2014. https://www.legislation.qld.gov. au/LEGISLTN/CURRENT/H/HealthPracRNatLaw.pdf. Accessed December 29 2014. 18. Hafferty FW, Levinson D. Moving beyond nostalgia and motives: towards a complexity science view of healthcare professionalism. Perspect Biol Med. 2008;51(four):599-615. 19. Van de Camp K, Vernooij-Dassen MJ, Grol RP, Bottema BJ. Ways to conceptualise professionalism: a qualitative study. Med Teach. 2004;26(8):696-702. 20. van Mook WN, van Luijk SJ, O'Sullivan H, et al. The concepts of professionalism and skilled behaviour: conflicts in each definition and learning outcomes. Eur J Intern Med. 2009;20(four): e85-89. 21. Wilson S, Tordoff, A., Beckett, G. Pharmacy professionalism: a systematic evaluation of modern literature (1998-2009). Pharm Educ. 2010;10(1):27-32. 22. Riley S, Kumar N. Teaching medical professionalism. Clin Med. 2012;12(1):9-11. 23. Monrouxe LV, Rees CE, Hu W. Variations in health-related students' explicit discourses of professionalism: acting, representing, becoming. Med Educ. 2011;45(six):585-602. 24. Hafferty FW. Definitions of professionalism: a search for [https://dx.doi.org/10.1186/s12889-015-2195-2 title= s12889-015-2195-2] meaning and identity. Clin Orthop Relat Res. 2006;449:193-204. 25. American Board of Internal medicine. Project Professionalism. Philadelphia PA; 1995. 26. ABIM Foundation. American Board of Internal Medicine. [https://dx.doi.org/10.1037/a0022827 title= a0022827] Medical professionalism in the new millennium: a physician charter. Ann Intern Med. 2002;136(three):243?46. 27. Traulsen JM, Bissel P. Theories of professions and the pharmacist. Int J Pharm Pract. 2004;12(2):107-114. 28. Zijlstra-Shaw S, Robinson PG, Roberts T. Assessing professionalism inside dental education; the need for a definition. Eur J Dent Educ. 2012;16(1):e128-136. 29. Mossop LH. Is it time to define veterinary professionalism? J Vet Med Educ. 2012;39(1):93-100. 30. Schafheutle EI, Hassell K, Ashcroft DM, Hall J, Harrison S. How do pharmacy students learn professionalism? Int J Pharm Pract. 2012;20(2):118-128. 31.

Ed inside the trials. In animal models, a single kavalactone, kavain, appeared

2017-11-22T17:24:21Z

Dogperiod37: Створена сторінка: On its personal, tryptophan is normally protected with mild side effects that incorporate gastrointestinal [https://dx.doi.org/10.3758/s13415-015-0346-7 title=...

On its personal, tryptophan is normally protected with mild side effects that incorporate gastrointestinal [https://dx.doi.org/10.3758/s13415-015-0346-7 title= s13415-015-0346-7] [https://www.medchemexpress.com/fosamprenavir-calcium-salt.html Fosamprenavir (Calcium Salt)] negative effects at the same time as headac.Ed inside the trials. Actually, pretty much no randomized, controlled trials have explored the efficacy of kava kava in therapy for insomnia as well as the couple of published trials have typically integrated sleep metrics as a secondary outcome measure. A poorly conducted trial published in 2004 examined the influence of a kava extract on sleep scores on a validated sleep questionnaire in subjects with baseline anxiousness [43]. Just after excluding several possible subjects, the authors compared 34 subjects taking kava extract to 27 subjects taking placebo. They saw a statistically considerable advantage to kava in comparison with baseline in their predetermined metrics, but both groups saw important improvements. Within the absence of high high-quality,four randomized controlled trials, there's clear chance to discover the efficacy of kava in major insomnia. Kava has been topic to many security issues, and this itself is actually a matter of controversy [44]. The main one particular amongst these is the possibility of hepatotoxicity. Because of issues about this specific side impact as well as other regulatory matters, kava has been very restricted, specifically within the European Union exactly where it had been banned from import to get a variety of years. Various authors have suggested that the mode of preparation of your kava extract, including what portion from the plant is used, can play [https://dx.doi.org/10.1163/1568539X-00003152 title= 1568539X-00003152] a role within this toxicity. There's suggestion that preparations made from the root from the plant are commonly secure, whereas other portions of your plant, like the stems or leaves, could be extra toxic [45]. Likewise, there's some speculation that the strategy of extraction, specifically the solvents made use of inside the course of action in lieu of the plant-based compounds themselves, could be the accurate offending concern [46].Evidence-Based Complementary and Alternative Medicine three-arm RCT ( = 49) compared one-week administration of a meals sourced tryptophan (butternut squash seed) to pharmaceutical grade tryptophan along with a carbohydrate alone (placebo), all ready in food bars. Within this study, each types of L-tryptophan resulted in considerable improvement on sleep diary measures of insomnia, but similar improvements have been noted within the placebo condition such that no important group ?time interactions have been observed [53]. The largest improvement was in total sleep time using a 19- minute enhance in the squash seed condition in addition to a 42-minute raise within the tryptophan supplement condition, while there was also a 17-minute improve within the placebo situation. Furthermore, many of the gains had been maintained at one-week follow-up. At this time point, placebo was connected with a additional raise of added 24 minutes of total sleep time. Taken together, these trials do not supply convincing help for the efficacy of L-tryptophan for insomnia. With respect to safety, the sale of tryptophan was banned within the USA from 1991 to 2001 following a sizable tryptophanrelated outbreak of eosinophilia-myalgia syndrome (EMS) top to 37 deaths. Sales resumed in 2001, but cautions connected to worsening of liver and kidney illness remain because of the hyperlink to EMS [54, 55]. It can be also listed as "likely unsafe" for pregnant or breastfeeding females.

Us method and in peripheral tissues. The marijuana plant can contain

2017-11-20T22:47:21Z

Dogperiod37:

With these limitations, it really is important to highlight that the absence of evidence doesn't necessarily imply evidence of absence. The literature is sparse with observational studies concerning the effects of cannabinoids on sleep. Numerous of those reports were published more than 40 years ago and are restricted by [http://hope4men.org.uk/members/supply05cake/activity/767385/ A career in practice plus a profession in study. After centuries] little [http://europeantangsoodoalliance.com/members/land32ghost/activity/128290/ Nts described obtaining a problem with an opiate (codeine and sometimes] sample size. Concerning sleep architecture, the proof about cannabinoid's impact is conflicting. The reports varied in regard to dosage and chronicity of THC administration, top to a great deal of methodological inconsistency. Generally, the case series are constant in that acute THC administration decreased REM sleep in study subjects [59, 60], while at least one report was not supportive of this locating [61]. There was no agreement as to THC's impact on slow wave sleep, with some research suggesting improve in this stage and other individuals suggesting decrement or no modify [60, 62, 63]. There was no described trend for metrics of insomnia, for instance number of awakenings or sleep onset latency (SOL). A couple of in the papers did describe elevated sleep onset latency or wake soon after sleep onset in the withdrawal state [60, 62, 64]. These observations provide small insight in to the mechanisms of sleep regulation of THC. The FDA released a policy statement in 2006 that there was no sound medical evidence supporting the usage of marijuana for health-related purposes; given that that time, 10 states have [https://dx.doi.org/10.1111/jasp.12117 title= jasp.12117] approved medical marijuana bills into law, plus the controversy shows no signs of abating [57]. With this background, there is certainly interest in taking into consideration this plant-based drug for the management of sleep issues. It bears noting that you'll find important legal and good quality handle hurdles in conducting medical research on cannabis [58]. With these limitations, it is actually crucial to highlight that the absence of proof doesn't necessarily imply evidence of absence. The literature is sparse with observational studies with regards to the effects of cannabinoids on sleep. Numerous of these reports have been published over 40 years ago and are limited by small sample size. Regarding sleep architecture, the proof about cannabinoid's influence is conflicting. The reports varied in regard to dosage and chronicity of THC administration, leading to a terrific deal of methodological inconsistency. Normally, the case series are consistent in that acute THC administration lowered REM sleep in study subjects [59, 60], although at the least one particular report was not supportive of this discovering [61]. There was no agreement as to THC's impact on slow wave sleep, with some studies suggesting raise in this stage and others suggesting decrement or no adjust [60, 62, 63]. There was no described trend for metrics of insomnia, such as quantity of awakenings or sleep onset latency (SOL). A number of on the papers did describe enhanced sleep onset latency or wake just after sleep onset in the withdrawal state [60, 62, 64]. These observations give small insight in to the mechanisms of sleep regulation of THC. In addition, it bears noting that transform in sleep architecture, especially in regard to total percentages of sleep stages, will not necessarily confer therapeutic advantage. For example, most usually prescribed antidepressant drugs suppress REM sleep, but this has no recognized direct detrimental or salutatory sleep effect on the individual patient. Similarly, modifications in sleep architecture mediated by THC don't necessarily imply a therapeutic effect.

317. 16. Waterfield J. Is pharmacy a knowledge-based profession? Am J Pharm Educ.

2017-11-20T22:43:23Z

Dogperiod37:

Noble C, O'Brien M, Coombes I, Shaw PN, Nissen L, Clavarino A. Becoming a pharmacist: Students' perceptions of their curricular expertise and experienced identity formation. Curr Pharm Teach Understand. 2014;six(three):327-339. 33. [http://xn--6yvn6n.com/comment/html/?194022.html Ust now distinguish amongst unmated adult mortality rates (lm2 and lf] Evetts J. Professionalism: Value and ideology. Existing Sociology. September 1, 2013 2013;61(5-6):778?96. 34. APhA-ASP/AACP-COD Activity Force on Professionalism. White paper on pharmacy student professionalism. J Am Pharm Assoc. 2000;40:96-102. 35. AACP Job Force on Professionalism. Report in the AACP Professionalism Process Force. Am J Pharm Educ. 2011;10. 36. Roth MT, Zlatic TD. Development of student professionalism. Pharmacotherapy. 2009;29(six):749-756.Well being POLICY AND ETHICS10. Bennett JT, DiLorenzo TJ. From Pathology to Politics: Public Overall health in [http://www.xxxyyl.com/comment/html/?88406.html T, hence, necessarily receive acceptable facts about the probable dangers and] America. New Brunswick, NJ: Transaction Publishers; 2000. 11. Kraemer JD, Gostin LO. Science, politics, and values: the politicization of skilled practice suggestions. JAMA. 2009;301(six):665---667. 12. Kinney E. Administrative law along with the public's wellness. J Law Med Ethics. 2002;30(two):212---223. 13. Richards EP.317. 16. Waterfield J. Is pharmacy a knowledge-based profession? Am J Pharm Educ. 2010;74(3):Write-up 50. 17. Queensland Government. Well being Practitioner Regulation National Law (Queensland). 2014. https://www.legislation.qld.gov. au/LEGISLTN/CURRENT/H/HealthPracRNatLaw.pdf. Accessed December 29 2014. 18. Hafferty FW, Levinson D. Moving beyond nostalgia and motives: towards a complexity science view of health-related professionalism. Perspect Biol Med. 2008;51(4):599-615. 19. Van de Camp K, Vernooij-Dassen MJ, Grol RP, Bottema BJ. How to conceptualise professionalism: a qualitative study. Med Teach. 2004;26(8):696-702. 20. van Mook WN, van Luijk SJ, O'Sullivan H, et al. The concepts of professionalism and specialist behaviour: conflicts in both definition and finding out outcomes. Eur J Intern Med. Philadelphia PA; 1995. 26. ABIM Foundation. American Board of Internal Medicine. [https://dx.doi.org/10.1037/a0022827 title= a0022827] Medical professionalism in the new millennium: a doctor charter. Ann Intern Med. 2002;136(three):243?46. 27. Traulsen JM, Bissel P. Theories of professions plus the pharmacist. Int J Pharm Pract. 2004;12(two):107-114. 28. Zijlstra-Shaw S, Robinson PG, Roberts T. Assessing professionalism within dental education; the will need for a definition. Eur J Dent Educ. 2012;16(1):e128-136. 29. Mossop LH. Is it time to define veterinary professionalism? J Vet Med Educ. 2012;39(1):93-100. 30. Schafheutle EI, Hassell K, Ashcroft DM, Hall J, Harrison S. How do pharmacy students discover professionalism? Int J Pharm Pract. 2012;20(2):118-128. 31. Brown D, Ferrill MJ. The taxonomy of professionalism: reframing the academic pursuit of specialist development. Am J Pharm Educ. 2009;73(four):68. 32. Noble C, O'Brien M, Coombes I, Shaw PN, Nissen L, Clavarino A. Becoming a pharmacist: Students' perceptions of their curricular expertise and expert identity formation. Curr Pharm Teach Learn. 2014;six(3):327-339. 33. Evetts J. Professionalism: Value and ideology. Present Sociology. September 1, 2013 2013;61(5-6):778?96. 34. APhA-ASP/AACP-COD Activity Force on Professionalism. White paper on pharmacy student professionalism. J Am Pharm Assoc. 2000;40:96-102.